Ondine Biomedical Inc (AIM:OBI) President and CTO Nicolas Loebel tells Proactive it has put a solid foundation for the future after a year of significant progress, the highlight of which was the company’s listing in London. The group raised $37.7 million from the IPO – cash that will be used to take its patented nasal photodisinfection technology through the clinical trial process. Currently, Ondine is in the process of recruiting patients for a phase II study to assess the potential of its Steriwave solution in a tie-up with HCA Healthcare, which will be complete by mid-year.
Ondine Biomedical 'funded well' as it sets solid foundations for upcoming clinical progress
